Registry of Lobbyists
Total Number of Communication Reports: 28
Monthly communication reports in the last 6 months: 0
| Subject matters | Details | Categories |
|---|---|---|
|
Health
|
Common Drug Review, as it relates to health technology assessments and drug product reimbursement recommendations.
|
Policies or Program
|
|
Budget, Economic Development, Federal-Provincial Relations, Health
|
Engagement on issues related to access to medicines, National Pharmacare, and a National Strategy for Drugs for Rare Diseases.
|
Policies or Program
|
|
Budget, Health
|
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
|
Policies or Program
|
|
Budget, Federal-Provincial Relations, Health
|
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals.
|
Policies or Program
|
|
Economic Development, Health, Intellectual Property
|
Innovation, Science and Economic Development Canada Innovation and Skills Strategy and other government policies and programs related to incentivizing research and development activities in Canada.
|
Policies or Program
|
|
Federal-Provincial Relations, Health
|
Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board
|
Regulation
|
Vertex is a global biotechnology company that discovers, develops and commercializes innovative medicines. We strive to improve the lives of patients suffering from rare and chronic disorders and are currently investing in multiple ongoing research programs targeting serious and life-threatening diseases.
Michael Siauw, General Manager – Canada
Address:
20 Bay Street
unit 1520
Toronto, ON M5J 2N8
Canada
Telephone number:
647-790-1600
Vertex Pharmaceuticals (Canada) Incorporated does not have any subsidiaries that could have a direct interest in the outcome of the undertaking